(-0.02%) 5 468.39 points
(-0.04%) 39 097 points
(0.25%) 17 762 points
(-0.63%) $80.32
(-4.32%) $2.64
(-0.87%) $2 310.50
(-0.10%) $28.84
(2.27%) $1 008.80
(0.28%) $0.936
(0.70%) $10.68
(0.47%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue...
Stats | |
---|---|
Today's Volume | 26.95M |
Average Volume | 0 |
Market Cap | 3.35M |
EPS | $-0.110 ( Q2 | 2022-08-04 ) |
Last Dividend | $0.310 ( 2013-10-28 ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.082 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0290 (6.80%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-09-01 | Buck Kristen K | Buy | 58 000 | Common Stock |
2022-09-01 | Buck Kristen K | Sell | 44 776 | Common Stock |
2022-09-01 | Mazzo David J | Buy | 150 000 | Common Stock |
2022-09-01 | Mazzo David J | Sell | 69 742 | Common Stock |
2022-01-13 | Mazzo David J | Sell | 6 471 | Common Stock |
INSIDER POWER |
---|
28.99 |
Last 95 transactions |
Buy: 2 781 590 | Sell: 342 279 |
Volume Correlation
Caladrius Biosciences, Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Caladrius Biosciences, Correlation - Currency/Commodity
Caladrius Biosciences, Financials
Annual | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.779 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.779 |
FY | 2020 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.530 |
FY | 2019 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-1.880 |
Financial Reports:
No articles found.
Caladrius Biosciences, Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.250 | 2011-04-04 |
Last Dividend | $0.310 | 2013-10-28 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 2 | -- |
Total Paid Out | $0.560 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 0.22 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
28 Oct 2013 | $0.310 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
04 Apr 2011 | $0.250 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
OXLC | Dividend Diamond | 2024-09-16 | Monthly | 14 | 15.03% | 9.60 |
DMLP | Dividend Diamond | 2024-04-26 | Quarterly | 22 | 10.71% | 9.35 |
OXSQ | Dividend Diamond | 2024-09-16 | Monthly | 21 | 12.73% | 9.02 |
ARLP | Dividend Royal | 2024-05-07 | Quarterly | 26 | 9.67% | 8.87 |
PNNT | Dividend Royal | 2024-06-14 | Monthly | 18 | 9.49% | 8.82 |
MFIC | Dividend Royal | 2024-06-11 | Quarterly | 21 | 10.89% | 8.79 |
SPOK | Dividend Royal | 2024-05-23 | Quarterly | 20 | 8.73% | 8.72 |
PSEC | Dividend Royal | 2024-06-25 | Monthly | 21 | 9.03% | 8.65 |
SBLK | Dividend Royal | 2024-06-06 | Quarterly | 17 | 13.10% | 8.63 |
GBDC | Dividend Royal | 2024-11-29 | Bi-Monthly | 15 | 8.53% | 8.62 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.283 | 1.200 | -9.44 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.441 | 1.500 | -6.01 | -9.02 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 21.00 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 21.03 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 21.00 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.441 | 2.00 | -0.480 | -0.960 | [0 - 30] |
freeCashFlowPerShareTTM | -1.445 | 2.00 | -0.722 | -1.445 | [0 - 20] |
debtEquityRatioTTM | 0 | -1.500 | 0 | 0 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0 | 1.000 | -1.111 | -1.111 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.965 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.240 | 1.000 | -0.125 | 0 | [1 - 100] |
returnOnEquityTTM | -0.441 | 2.50 | -3.87 | -9.02 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.445 | 2.00 | -0.482 | -1.445 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.441 | 2.00 | -0.480 | -0.960 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.0197 | 1.500 | -3.46 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -1.941 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Caladrius Biosciences,
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. Caladrius Biosciences, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators